So much for the turkey. Staff at US vaccine maker Moderna spent Thanksgiving studying the Omicron coronavirus variant. Moderna’s shares have since risen by a third, as have those of German peer BioNTech. That is a measure of the hopes pinned on mRNA pioneers in the face of the latest threat.
感恩節(jié)就這么完了。美國疫苗制造商莫德納(Moderna)的工作人員在感恩節(jié)期間研究了Omicron變種。莫德納的股價(jià)自此上漲了三分之一，德國同行BioNTech也是如此。這表明了人們在面臨最新威脅時(shí)對mRNA先驅(qū)所寄托的希望。
您已閱讀12%（406字），剩余88%（2858字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。